Is Lineage Cell Therapeutics Stock a good buy in 2023, according to Wall Street analysts?
The consensus among 2 Wall Street analysts covering (NYSEMKT: LCTX) stock is to Strong Buy LCTX stock.
Out of 2 analysts, 1 (50%) are recommending LCTX as a Strong Buy, 1 (50%) are recommending LCTX as a Buy, 0 (0%) are recommending LCTX as a Hold, 0 (0%) are recommending LCTX as a Sell, and 0 (0%) are recommending LCTX as a Strong Sell.
According to 2 Wall Street analysts that have issued a 1 year LCTX price target, the average LCTX price target is $6.50, with the highest LCTX stock price forecast at $7.00 and the lowest LCTX stock price forecast at $6.00.
On average, Wall Street analysts predict that Lineage Cell Therapeutics's share price could reach $6.50 by Aug 11, 2024. The average Lineage Cell Therapeutics stock price prediction forecasts a potential upside of 450.85% from the current LCTX share price of $1.18.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.